Strategy

Dec 01, 2005
Pharmaceutical Executive
In an article for the New York Times, reporter Damien Cave pointed out how few heroes have been publicly recognized by the Administration in the current war. Despite the fact that there have been incredible acts of heroism and gutsy leadership on the ground of this Iraq war, the powers that be, for the most part, are calling no attention to it—at least no prime-time attention. Damien's most damning example came from Major Bruce Norton, a military historian and author of Encyclopedia of American Military Heroes, who recounted how a Marine recently received his Navy Cross, the second-highest military honor—not with ceremony and honor, but in the mail.
Nov 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Valeant is banking on Viramidine, a pro-drug of its longtime cash cow, ribavirin, to catapult the company to the next level.
Oct 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
When it comes to infectious diseases, biotech start-up Idenix is on a mission: to provide patients with treatments that are more effective, more tolerable, and safer than current standards of care. Though small, the Cambridge, Massachusetts-based company is well poised to become a leader in the global antiretroviral market: It has experienced top management, a strong background in medicinal chemistry and drug discovery, and a pipeline of novel treatments for hepatitis B and C and HIV. Until a couple years ago, all Idenix lacked was a financial backer to help pay the way.
Oct 01, 2005
Pharmaceutical Executive
Market researchers often fail to realize that whenever they collect competitor information they are in fact collecting competitive intelligence. The same is true in reverse.
Oct 01, 2005
Pharmaceutical Executive
There comes a point when people have enough stuff in their lives, but they can never have enough meaning. Leaders have to find opportunities for their eams to do more than turn the machine of profit.
Oct 01, 2005
Pharmaceutical Executive
To get along with the CFO, drug companies need to express more data in units that a health plan can integrate into its own internal actuarial analysis. The financial decision makers at a health plan want to know how a new drug affects the value of expected claims on the whole.
Oct 01, 2005
Pharmaceutical Executive
No brand manufacturers plan to market generic versions of their own product, at least not until the patent expires. And why would they? As long as the branded version enjoys patent protection, marketing a cut-rate product would eat away profit margin during the years when a drug makes the most money.
Oct 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Poker has become one on the most popular attractions on television and the Internet, right up there with online auctions. And if the two were ever combined—so that players could auction off their hand early in a game, with several rounds of cards remaining to be dealt—bidders might seek advice from folks in pharmaceutical business development. Because that's what we do. When we buy or sell the rights to a compound in development, we are putting a price on a gamble.
Oct 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
In some cases simply contemplating a potential partnership will lead a company to reconsider some of its basic business strategies. That's fine, as long as everyone is clear on one thing: The important goal isn't to make a partnership. The important goal is to advance the business.
Oct 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Martin Soeters (pronounced soo't rs) has dedicated a quarter century—almost half his life—to the company at which he's now president of US operations. Novo Nordisk, where Soeters has worked since 1980—in various executive roles and locations, from The Netherlands (his homeland) to Belgium to France—is a leader in diabetes treatment, with the largest portfolio in the industry.
native1_300x100
lorem ipsum